SEC Form 4 · accession 0001209191-19-009508
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Isaac E. Ciechanover
Officer — Chief Executive Officer · Director
Period of report
Feb 9, 2019
Accepted (ET)
Feb 12, 2019 · 7:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 9, 2019 | F | 20,324 | $38.49 | D | 334,618 | D | |
| Common StockF3,F4 | Feb 11, 2019 | S | 3,900 | $38.52 | D | 346,038 | I | See Footnote |
| Common StockF5,F4 | Feb 12, 2019 | S | 3,900 | $39.01 | D | 342,138 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld to cover tax obligation from settlement of vested restricted stock units.
- F2Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018.
- F3The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.12 to $39.07. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
- F5The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.75 to $39.24. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.